Screening for glucose intolerance in polycystic ovary syndrome: hemoglobin A1C, fasting blood glucose or oral glucose tolerance test?

References

• Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Human Reprod 2010;16(4):347-263
   Web of Science ®Google Scholar
• Azziz R, Carmina E, Dewailly D, et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006;91:4237-45
   PubMed Web of Science ®Google Scholar
• Hollinrake E, Abreu A, Maifield M, et al. Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertil Steril 2007;87(6):1369-76
   PubMed Web of Science ®Google Scholar
• Yildiz BO, Bozdag G, Yapici Z, et al. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod 2012;27(10):3067-73
   PubMed Web of Science ®Google Scholar
• Salley KE, Wickham EP, Cheang KI, et al. Glucose intolerance in polycystic ovary syndrome – a position statement of the Androgen Excess Society. J Clin Endocrinol Metab 2007;92:4546-56
   PubMed Web of Science ®Google Scholar
• Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts health across the lifespan. BMC Med 2010;8:41
   PubMed Web of Science ®Google Scholar
• Stepto NK, Cassar S, Joham AE, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycemic-hyperinsulinemic clamp. Hum Reprod 2013;28(3):777-84
   PubMed Web of Science ®Google Scholar
• Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 2002;77(6):1095-105
   PubMed Web of Science ®Google Scholar
• Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38(9):1165-74
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovarian syndrome. Diabetes Care 1999;22:141-6
   PubMed Web of Science ®Google Scholar
• Flannery CA, Rackow B, Cong X, et al. Polycystic ovary syndrome in adolescence: impaired glucose tolerance occurs across the spectrum of BMI. Pediatr Diabetes 2013;14(1):42-9
   PubMed Web of Science ®Google Scholar
• Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 2005;90(6):3236-42
   PubMed Web of Science ®Google Scholar
• Lerchbaum E, Schwetz V, Giuliani A, Obermayer-Pietsch B. Assessment of glucose metabolism in polycystic ovary syndrome: hbA1c or fasting glucose compared with the oral glucose tolerance test as a screening method. Hum Reprod 2013;28(9):2537-44
   PubMed Web of Science ®Google Scholar
• Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374(9702):1677-86
   PubMed Web of Science ®Google Scholar
• Tomlinson J, Milward A, Stenhouse E, Pinkney J. Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced? Diabet Med 2010;27(5):498-515
   PubMed Web of Science ®Google Scholar
• Stovall DW, Bailey AP, Pastore LM. Assessment of insulin resistance and impaired glucose tolerance in lean women with polycystic ovary syndrome. J Womens Health (Larchmt) 2011;20(1):37-43
   PubMed Web of Science ®Google Scholar
• Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-9
   PubMed Web of Science ®Google Scholar
• Solomon CG, Hu FB, Dunaif A, et al. Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA 2001;286(19):2421-6
   PubMed Web of Science ®Google Scholar
• Carmina E. Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines. Minerva Ginecol 2004;56(1):1-6
   PubMedGoogle Scholar
• Wang ET, Calderon-Margalit R, Cedars MI, et al. Polycystic ovary syndrome and risk for long-term diabetes and dyslipidemia. Obstet Gynecol 2011;117(1):6-13
   PubMed Web of Science ®Google Scholar
• Mani H, Levy MJ, Davies MJ, et al. Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study. Clin Endocrinol (Oxf) 2013;78(6):926-34
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81(1):19-25
   Web of Science ®Google Scholar
• Boudreaux MY, Talbott EO, Kip KE, et al. Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8-year follow-up. Curr Diab Rep 2006;6(1):77-83
   PubMedGoogle Scholar
• Gambineri A, Patton L, Altieri P, et al. Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study. Diabetes 2012;61(9):2369-74
   PubMed Web of Science ®Google Scholar
• Morgan CL, Jenkins-Jones S, Currie CJ, Rees DA. Evaluation of adverse outcome in young women with polycystic ovary syndrome versus matched, reference controls: a retrospective, observational study. J Clin Endocrinol Metab 2012;97(9):3251-60
   PubMed Web of Science ®Google Scholar
• Azziz R, Carmina E, Dewailly D, et al. The androgen excess and PCOS society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2006;91(2):456-88
   Google Scholar
• Ding EL, Song Y, Manson JE, et al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med 2009;361(12):1152-63
   PubMed Web of Science ®Google Scholar
• Palomba S, Falbo A, Russo T, et al. The risk of a persistent glucose metabolism impairment after gestational diabetes mellitus is increased in patients with polycystic ovary syndrome. Diabetes Care 2012;35(4):861-7
   PubMed Web of Science ®Google Scholar
• Boomsma CM, Eijkemans MJ, Hughes EG, et al. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006;12(6):673-83
   PubMed Web of Science ®Google Scholar
• Kjerulff LE, Sanchez-Ramos L, Duffy D. Pregnancy outcomes in women with polycystic ovary syndrome: a metaanalysis. Am J Obstet Gynecol 2011;204(6):558.e1-6
   Web of Science ®Google Scholar
• Joham AE, Ranasinha S, Zoungas S, et al. Gestational diabetes and type 2 diabetes in reproductive-aged women with polycystic ovary syndrome. J Clin Endocrinol Metab 2014;99(3):E447-52
   PubMed Web of Science ®Google Scholar
• Landon MB, Spong CY, Thom E, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med 2009;361(14):1339-48
   PubMed Web of Science ®Google Scholar
• Metzger BE, Lowe LP, Dyer AR, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008;358(19):1991-2002
   PubMed Web of Science ®Google Scholar
• Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 2002;25(10):1862-8
   PubMed Web of Science ®Google Scholar
• Holte J, Bergh T, Berne C, et al. Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J Clin Endocrinol Metab 1994;78(5):1052-8
   PubMed Web of Science ®Google Scholar
• Dunaif A, Finegood DT. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81(3):942-7
   PubMed Web of Science ®Google Scholar
• O’Meara N, Blackman JD, Ehrmann DA, et al. Defects in beta-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1993;76:1241-7
   PubMed Web of Science ®Google Scholar
• Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800
   PubMed Web of Science ®Google Scholar
• Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352(12):1223-36
   PubMed Web of Science ®Google Scholar
• Malin SK, Kirwan JP, Sia CL, Gonzalez F. Glucose-stimulated oxidative stress in mononuclear cells is related to pancreatic beta-cell dysfunction in polycystic ovary syndrome. J Clin Endocrinol Metab 2014;99(1):322-9
   PubMed Web of Science ®Google Scholar
• Musso C, Cochran E, Moran SA, et al. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndrome): a 30-year prospective. Medicine (Baltimore) 2004;83(4):209-22
   PubMed Web of Science ®Google Scholar
• Lungu AO, Zadeh ES, Goodling A, et al. Insulin resistance is a sufficient basis for hyperandrogenism in lipodystrophic women with polycystic ovary syndrome. J Clin Endocrinol Metab 2012;97(2)):563-7
   PubMed Web of Science ®Google Scholar
• Meyer C, McGrath BP, Teede HJ. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab 2005;90:5711-16
   PubMed Web of Science ®Google Scholar
• Meyer C, McGrath BP, Cameron J, et al. Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:4630-5
   PubMed Web of Science ®Google Scholar
• Orio F Jr, Palomba S, Cascella T, et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89(9):4588-93
   PubMed Web of Science ®Google Scholar
• Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000;20(11):2414-21
   PubMed Web of Science ®Google Scholar
• Christian RC, Dumesic DA, Behrenbeck T, et al. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88(6):2562-8
   PubMed Web of Science ®Google Scholar
• Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS consensus workshop group. Fertil Steril 2012;97:28-38
   PubMed Web of Science ®Google Scholar
• Dahlgren E, Janson PO, Johansson S, et al. Polycystic ovary syndrome and risk for myocardial infarction: evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992;71:599-604
   PubMed Web of Science ®Google Scholar
• Solomon CG, Hu FB, Dunaif A, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002;87(5):2013-17
   PubMed Web of Science ®Google Scholar
• Shaw LJ, Bairey Merz CN, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institute of Health—National Heart, Lung, and Blood Institute sponsored Women’s Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008 93(4)):1276-84
   PubMed Web of Science ®Google Scholar
• Palmert MR, Gordon CM, Kartashov AI, et al. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:1017-23
   PubMed Web of Science ®Google Scholar
• Veltman-Verhulst SM, Goverde AJ, van Haeften TW, Fauser BC. Fasting glucose measurement as a potential first step screening for glucose metabolism abnormalities in women with anovulatory polycystic ovary syndrome. Hum Reprod 2013;28(8)):2228-34
   PubMed Web of Science ®Google Scholar
• Pesant MH, Baillargeon JP. Clinically useful predictors of conversion to abnormal glucose tolerance in women with polycystic ovary syndrome. Fertil Steril 2011;95:210-15
   PubMed Web of Science ®Google Scholar
• Magnussen LV, Mumm H, Anderson M, Glintborg D. Hemoglobin A1C as a tool for the diagnosis of type 2 diabetes in 208 premenopausal women with polycystic ovary syndrome. Fertil Steril 2011;96:1275-80
   PubMed Web of Science ®Google Scholar
• Hurd WW, Abdel-Rahman MY, Ismail SA, et al. Comparison of diabetes mellitus and insulin resistance screening methods for women with polycystic ovary syndrome. Fertil Steril 2011;96(4):1043-7
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2014. Diabetes Care 2014;37(Suppl 1):S14-80
   PubMed Web of Science ®Google Scholar
• Gagnon C, Baillargeon JP. Suitability of recommended limits for fasting glucose tests in women with polycystic ovary syndrome. CMAJ 2007;176(7):933-8
   PubMed Web of Science ®Google Scholar
• Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diabetes Care 1999;22:920-4
   PubMed Web of Science ®Google Scholar
• Celik C, Abali R, Bastu E, et al. Assessment of impaired glucose tolerance prevalence with hemoglobin A1C and oral glucose tolerance test in 252 Turkish women with polycystic ovary syndrome: a prospective, controlled study. Hum Reprod 2013;28(4):1062-8
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011;34(Suppl 1):S62-9
   PubMed Web of Science ®Google Scholar
• International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327-34
   PubMed Web of Science ®Google Scholar
• Golland IM, Vaughan Williams CA, Shalet SM, et al. Lack of predictive value of HbA1 for impaired glucose tolerance in polycystic ovary syndrome. Gynecol Endocrinol 1989;3(3):229-35
   PubMed Web of Science ®Google Scholar
• Mortada R, Comeford K, Kallail KJ, Karakas SE. Utility of hemoglobin-A1C in nondiabetic women with polycystic ovary syndrome. Endocr Pract 2013;19(2):284-9
   PubMed Web of Science ®Google Scholar
• Wongwananuruk T, Rattanachaiyanont M, Leerasiri P, et al. The usefulness of homeostatic measurement assessment-insulin resistance (HOMA-IR) for detection of glucose intolerance in Thai women of reproductive age with polycystic ovary syndrome. Int J Endocrinol 2012;2012:571035
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Kouli C, Alexandraki K, Spina G. Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89(3):1273-6
   PubMed Web of Science ®Google Scholar
• Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013;98(12):4565-92
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman MY, Jackson LW, Rodewald KJ, et al. Polycystic ovary syndrome and diabetes screening: a survey of gynecologists and reproductive endocrinologists. Eur J Obstet Gynecol Reprod Biol 2012;162(2):178-81
   PubMed Web of Science ®Google Scholar
• American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee. American Association of Clinical Endocrinologists (AACE) position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. Endocr Pract 2005;11(2):126-34
   PubMedGoogle Scholar
• ACOG Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin No. 108: polycystic ovary syndrome. Obstet Gynecol 2009;114(4):936-49
   PubMedGoogle Scholar
• Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010;95(5):2038-49
   PubMed Web of Science ®Google Scholar
• Barber TM, Franks S. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. Expert Rev Endocrinol Metab 2013;8(5):427-9
   PubMedGoogle Scholar
• Norman RJ, Masters L, Milner CR, et al. Relative risk of conversion from normoglycemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovary syndrome. Hum Reprod 2001;16(9):1995-8
   PubMed Web of Science ®Google Scholar
• Misra A. Prevention of type 2 diabetes: the long and winding road. Lancet 2009;374(9702):1655-6
   PubMed Web of Science ®Google Scholar
• Thomson RL, Buckley JD, Noakes M, et al. The effect of a hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile, and reproductive function in overweight and obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93:3373-80
   PubMed Web of Science ®Google Scholar
• Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2011((7)):CD007506
   Google Scholar
• Domecq JP, Prutsky G, Mullan RJ, et al. Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis. J Clin Endocrinol Metab 2013;98(12):4655-63
   PubMed Web of Science ®Google Scholar
• Pasquali R, Gambineri A, Cavazza C, et al. Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. Eur J Endocrinol 2011;164(1):53-60
   PubMed Web of Science ®Google Scholar
• Moran LJ, Ko H, Misso M, et al. Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines. J Acad Nutr Diet 2013;113(4):520-45
   PubMed Web of Science ®Google Scholar
• Legro RS. Obesity and PCOS: implications for diagnosis and treatment. Semin Reprod Med 2012;30(6):496-506
   PubMed Web of Science ®Google Scholar
• Ladson G, Dodson WC, Sweet SD, et al. The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double blind study. Fertil Steril 2011;95(3):1059-66
   PubMed Web of Science ®Google Scholar
• Hoeger KM, Kochman L, Wixom N, et al. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 2004;82:421-9
   PubMed Web of Science ®Google Scholar
• Geller DH, Pacaud D, Gordon CM, Misra M. State of the art review: emerging therapies: the use of insulin sensitizers in the treatment of adolescents with polycystic ovary syndrome (PCOS). Int J Pediatr Endocrinol 2011;9:1-19
   Google Scholar
• Bargiota A, Diamanti-Kandarakis E. The effects of old, new and emerging medicines on metabolic aberrations in PCOS. Ther Adv Endocrinol Metab 2012;3(1):27-47
   PubMedGoogle Scholar
• Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998;138(3):269-74
   PubMed Web of Science ®Google Scholar
• Lord JM, Flight IHK, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and metaanalysis. BMJ 2003;327(7421):951-3
   PubMed Web of Science ®Google Scholar
• Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 2002;87(4):1555-9
   PubMed Web of Science ®Google Scholar
• Sharma ST, Wickham EP 3rd, Neslter JE. Changes in glucose tolerance with metformin treatment in polycystic ovary syndrome: a retrospective analysis. Endocr Pract 2007;13(4):373-9
   PubMedGoogle Scholar
• Ladson G, Dodson WC, Sweet SD, et al. Effects of metformin in adolescents with polycystic ovary syndrome undertaking lifestyle therapy: a pilot randomized double-blind study. Fertil Steril 2011;95:2595-8
   PubMed Web of Science ®Google Scholar
• Tang T, Lord JM, Norman RJ, et al. Insulin sensitizing drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhea and subfertility. Cochrane Database Syst Rev 2012;5:CD003053
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82(7):2108-16
   PubMed Web of Science ®Google Scholar
• Dunaif A, Scott D, Finegood D, et al. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81(9):3299-306
   PubMed Web of Science ®Google Scholar
• Marshall JC, Dunaif A. Should all women with PCOS be treated for insulin resistance? Fertil Steril 2012;97(1):18-22
   PubMed Web of Science ®Google Scholar
• Nader S. Treatment for polycystic ovary syndrome: a critical appraisal of treatment options. Expert Rev Endocrinol Metab 2008;3(3):349-59
   PubMedGoogle Scholar
• Mechanick JI, Kuhsner RF, Sugerman HJ, et al. American association of clinical endocrinologists, the obesity society, and American Society for Metabolic & Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Endocr Pract 2008;14(Suppl 1)):1-83
   PubMedGoogle Scholar
• Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, et al. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 2005;90:6364-9
   PubMed Web of Science ®Google Scholar
• Maggard MA, Shugarman LR, Suttorp M, et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med 2005;142(7):547-59
   PubMed Web of Science ®Google Scholar
• Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351(26):2683-93
   PubMed Web of Science ®Google Scholar
• Cagnacii A, Paoletti AM, Renzi A, et al. Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel. J Clin Endocrinol Metab 2003;88:3621-5
   PubMed Web of Science ®Google Scholar
• WHO. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus. WHO, Geneva, Switzerland; 1999
   Google Scholar